{
    "title": "RACE for Children Act",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Research to Accelerate Cures and \nEquity for Children Act'' or the ``RACE for Children Act''.\n\nSEC. 2. REQUIRED PEDIATRIC ASSESSMENTS.\n\n    (a) Molecular Targets Regarding Cancer Drugs.--Section 505B of the \nFederal Food, Drug, and Cosmetic Act (21 U.S.C. 355c) is amended--\n            (1) in subsection (a)(1)--\n                    (A) in subparagraph (A), by striking ``or'' at the \n                end;\n                    (B) in subparagraph (B), by inserting ``or'' after \n                ``administration,''; and\n                    (C) by inserting after subparagraph (B) the \n                following:\n                    ``(C) under section 505 of this Act or section 351 \n                of the Public Health Service Act, as described in \n                subparagraph (A) or (B), that is directed at a \n                molecular target present in one or more cancers in one \n                or more pediatric populations,''; and\n            (2) in subsection (b)(1)--\n                    (A) by amending subparagraph (A)(i) to read as \n                follows:\n                    ``(A)(i) the drug or biological product is used for \n                a substantial number of pediatric patients--\n                            ``(I) for the labeled indications; or\n                            ``(II) with respect to one or more specific \n                        molecular targets present in cancers in \n                        pediatric populations; and'';\n                    (B) by amending subparagraph (B) to read as \n                follows:\n                    ``(B) there is reason to believe that the drug or \n                biological product would represent a meaningful \n                therapeutic benefit over existing therapies for \n                pediatric patients--\n                            ``(i) for one or more of the claimed \n                        indications; or\n                            ``(ii) with respect to one or more specific \n                        molecular targets present in cancers in \n                        pediatric populations; or''; and\n                    (C) by amending paragraph (2) of subsection (c) to \n                read as follows:\n            ``(2) the drug or biological product is in a class of \n        products, is for an indication, or is directed at a specific \n        molecular target present in cancers in pediatric populations, \n        for which there is need for additional options.''.\n    (b) Early Meeting on Pediatric Study Plan.--\n            (1) In general.--Clause (i) of section 505B(e)(2)(C) of the \n        Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(e)(2)(C)) \n        is amended to read as follows:\n                            ``(i) shall meet with the applicant--\n                                    ``(I) if requested by the applicant \n                                with respect to a drug that is directed \n                                at a molecular target that is present \n                                in one or more cancers in one or more \n                                pediatric populations, as described in \n                                subsection (a)(1)(C), to discuss, not \n                                later than the end-of-Phase1 meeting \n                                (as such term is used in section \n                                312.82(b) of title 21, Code of Federal \n                                Regulations, or successor regulations), \n                                preparation of the initial pediatric \n                                study plan;\n                                    ``(II) to discuss the initial \n                                pediatric study plan as soon as \n                                practicable, but not later than 90 \n                                calendar days after the receipt of such \n                                plan under subparagraph (A); and\n                                    ``(III) to discuss any scientific \n                                or operational challenges that may be \n                                the basis of a deferral under \n                                subsection (a)(3) or a full or partial \n                                waiver under subsection (a)(4);''.\n            (2) Conforming changes.--Section 505B(e) of the Federal \n        Food, Drug, and Cosmetic Act (21 U.S.C. 355c(e)) is amended--\n                    (A) in the heading of paragraph (2), by striking \n                ``meeting'' and inserting ``meetings'';\n                    (B) in the heading of paragraph (2)(C), by striking \n                ``Meeting'' and inserting ``Meetings'';\n                    (C) in clauses (ii) and (iii) of paragraph (2)(C), \n                by striking ``no meeting'' each place it appears and \n                inserting ``no meeting under clause (i)(II)''; and\n                    (D) in paragraph (3) by striking ``meeting under \n                paragraph (2)(C)(i)'' and inserting ``meeting under \n                paragraph (2)(C)(i)(II)''.\n    (c) Orphan Drugs.--Section 505B(k) of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 355c(k)) is amended by inserting ``except in \nthe case of a drug or biological product that is the subject of an \napplication described in subsection (a)(1)(C),'' after ``regulation,''.\n    (d) Guidance.--Not later than 1 year after the date of enactment of \nthis Act, the Secretary of Health and Human Services, acting through \nthe Commissioner of Food and Drugs, shall issue guidance on the \nimplementation of this section (including the amendments made by this \nsection), including study designs and molecular targets likely to be \npresent in one or more cancers in pediatric populations that are \nappropriate for assessment under the amendments made by this Act.\n    (e) Applicability.--This Act and the amendments made by this Act \napply with respect to applications for a drug submitted under section \n505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or \nsection 351 of the Public Health Service Act (42 U.S.C. 262) on or \nafter the date that is 18 months after the date of enactment of this \nAct.\n    (f) Report to Congress.--Not later than July 12, 2021, the \nSecretary of Health and Human Services, acting through the Commissioner \nof Food and Drugs, shall submit to Congress a report on the \nimplementation of the amendments made by this section, together with \nany recommendations of the Secretary regarding such amendments.\n    (g) Rule of Construction.--Nothing in this Act, including the \namendments made by this Act, shall limit the authority of the Secretary \nof Health and Human Services to issue written requests under section \n505A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355a)."
}